Results 31 to 40 of about 26,086 (200)

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis

OncoImmunology, 2018
Multiple non-redundant immunosuppressive pathways co-exist in the tumor microenvironment and their co-targeting can increase clinical responses. Indeed, concurrent blockade of CTLA-4 and PD-1 in patients with advanced melanoma increased clinical ...
Heidi Harjunpää, Stephen J. Blake, Elizabeth Ahern, Stacey Allen, Jing Liu, Juming Yan, Viviana Lutzky, Kazuyoshi Takeda, Amy Roman Aguilera, Camille Guillerey, Deepak Mittal, Xian Yang Li, William C. Dougall, Mark J. Smyth, Michele W. L. Teng   +14 more
doaj   +1 more source

TIGIT predominantly regulates the immune response via regulatory T cells [PDF]

, 2015
Coinhibitory receptors are critical for the maintenance of immune homeostasis. Upregulation of these receptors on effector T cells terminates T cell responses, while their expression on Tregs promotes their suppressor function. Understanding the function
Teng, Michele W L, Teng, Michele W. L., Anderson, Ana C., Kurtulus, Sema, Ngiow, Shin-Foong, Michele W.L. Teng, Sakuishi, Kaori, Smyth, Mark J, Anderson, Ana C, Mark J. Smyth, Vijay K. Kuchroo, Ana C. Anderson, Joller, Nicole, Kuchroo, Vijay K, Kaori Sakuishi, Tan, Dewar J., Smyth, Mark J., Nicole Joller, Dewar J. Tan, Kuchroo, Vijay K., Shin-Foong Ngiow, Tan, Dewar J, Sema Kurtulus   +22 more
core   +1 more source

TIGIT is a key inhibitory checkpoint receptor in lymphoma

, 2023
Background PD-1 checkpoint blockade therapy (CBT) has greatly benefited patients with select solid tumors and lymphomas but has limited efficacy against diffuse large B-cell lymphoma (DLBCL).
James Godfrey, Ekaterina Postovalova, Yuanyuan Zha, Alan Cooper, Xiufen Chen, Aleksander Bagaev, Nicole Sunseri, Yuriy Popov, Dmitry Zarubin, Girish Venkataraman, Krystle Nomie, Sravya Tumuluru, Connor Jacobson, Jovian Yu, Arina Varlamova, Justin P Kline, Sonali M Smith, Zhongmin Xiang   +17 more
core   +1 more source

Programmed cell death protein-1 and other inhibitory receptors expressed by regulatory T cells as a restraining factor of checkpoint therapy [PDF]

Archive of Oncology
The effectiveness of anti-PD-1/PD-L1 targeted therapies focused on the antitumor immune response restoration in the treatment of melanoma and several other tumors has renewed trust in immunotherapy potential. Despite inspiring enthusiasm that led both to
Batorov Egor V., Ostanin Alexander, Chernykh Elena   +2 more
doaj   +1 more source

Clinical significance of CD8+ T cell immunoreceptor with Ig and ITIM domains+ in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy

OncoImmunology, 2019
Gastric cancer (GC) development and progression is significantly associated with tumour immune escape. T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibits T-cell responses and is associated with human cancers and T cell exhaustion phenotypes,
Weiwei Tang, Xiongxiong Pan, Di Han, Dawei Rong, Minghui Zhang, Lulu Yang, Jie Ying, Hua Guan, Ziyi Chen, Xuehao Wang   +9 more
doaj   +1 more source

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

OncoImmunology, 2021
PD1 blockade to reinvigorate T cells has become part of standard of care for patients with NSCLC across disease stages. However, the majority of patients still do not respond.
Marina Martinez, Soyeon Kim, Naomi St. Jean, Shaun O’Brien, Lurong Lian, Jing Sun, Raluca I. Verona, Edmund Moon   +7 more
doaj   +1 more source

Structural and functional characterization of a monoclonal antibody blocking TIGIT

mAbs, 2022
TIGIT is an immune checkpoint receptor that is expressed on subsets of activated T cells and natural killer (NK) cells. Several ligands for TIGIT, including poliovirus receptor (PVR), are expressed on cancer cells and mediate inhibitory signaling to ...
Bo-Seong Jeong, Hyemi Nam, Jeewon Lee, Hye-Young Park, Ki Joon Cho, Joong Hyuk Sheen, Eunjung Song, Meesook Oh, Sunggeun Lee, Hyemin Choi, Jung-Eun Yang, Munkyung Kim, Byung-Ha Oh   +12 more
doaj   +1 more source

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease [PDF]

, 2020
Objectives Signals at the contact site of antigen-presenting cells (APCs) and T cells help orchestrate the adaptive immune response. CD155 on APCs can interact with the stimulatory receptor DNAM1 or inhibitory receptor TIGIT on T cells.
Jacobs, Marleen, Olde Nordkamp, Michel, Leijten, Emmerik, Pouw, Juliëtte, Radstake, Timothy, Boes, Marianne, Immuno/reuma onderzoek 2 (Boes), Onderzoek, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, CTI Boes, MS Reumatologie/Immunologie/Infectie, CTI CFF, Child Health, Unit Opleiding Reumat./Klin. Immunologie   +14 more
core  

Expression and Clinical Significance of TIGIT in Primary Breast Cancer

International Journal of General Medicine, 2023
Limin Tang,1 Min Sha,2 Ting Guo,2 Huimin Lu,2 Jingyu Qian,2 Qixiang Shao,1 Jun Ye2 1Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 2Department of Central Laboratory, The Affiliated ...
Tang L, Sha M, Guo T, Lu H, Qian J, Shao Q, Ye J   +6 more
doaj  

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

OncoImmunology, 2018
The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity.
Alice L. Hung, Russell Maxwell, Debebe Theodros, Zineb Belcaid, Dimitrios Mathios, Andrew S. Luksik, Eileen Kim, Adela Wu, Yuanxuan Xia, Tomas Garzon-Muvdi, Christopher Jackson, Xiaobu Ye, Betty Tyler, Mark Selby, Alan Korman, Bryan Barnhart, Su-Myeong Park, Je-In Youn, Tamrin Chowdhury, Chul-Kee Park, Henry Brem, Drew M. Pardoll, Michael Lim   +22 more
doaj   +1 more source